Do not share your Ozempic® pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
NovoCare® is here to help patients like you access and afford their medications. This site is available 24/7, and we offer live support through the phone numbers listed below.
Further down on this page, you’ll also find answers to frequently asked questions.
Need assistance?
We’re here for you
NovoCare® is here to help patients like you access and afford their medications. This site is available 24/7, and we offer live support through the phone numbers listed below.
Further down on this page, you’ll also find answers to frequently asked questions.
Monday-Friday, 8:00 am-11:00 pm
Saturday, 11:00 am-7:00 pm
Eastern Standard Time
Monday-Friday, 8:00 am-8:00 pm
Eastern Standard Time
Report a side effect or issue with your medication
Please submit a form online or by calling 800‑727‑6500
Frequently Asked Questions
Medicines are incredibly expensive to research and develop in general. It can take billions of dollars to bring a single safe and effective medicine to market.
Your insurance situation also factors into the price you pay for medicine. Novo Nordisk has teams of people negotiating with insurers to ensure better coverage for our products. Ultimately, though, it’s up to the insurer to decide whether to cover a product and the level of coverage. Additionally, your insurance provider will determine whether you pay a flat fee, called a “copay,” or a percentage of the total cost, called “coinsurance."
To find out if your insurance covers your medicine, make a selection below.
Diabetes medicines
Fiasp® (insulin aspart) injection 100 U/mL
Levemir® (insulin detemir) injection 100 U/mL
NovoLog® (insulin aspart) injection 100 U/mL
NovoLog® Mix 70/30 (insulin aspart protamine and insulin aspart) injectable suspension 100 U/mL
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg
RYBELSUS® (semaglutide) tablets 7 mg or 14 mg
Tresiba® (insulin degludec) injection 100 U/mL or 200 U/mL
Victoza® (liraglutide) injection 1.2 mg or 1.8 mg
Xultophy® 100/3.6 (insulin degludec and liraglutide) injection 100 U/mL and 3.6 mg/mL
Obesity medicines
Saxenda® (liraglutide) injection 3 mg
Wegovy® (semaglutide) injection 2.4 mg
Primary hyperoxaluria type 1 (PH1) medicine
For coverage information, connect with a NovoCare® representative at 844‑906‑5099
Growth-related disorders medicines
For coverage information about Novo Nordisk growth-related disorders medicines, connect with a NovoCare® representative at 888‑668‑6444
Hemophilia and rare bleeding disorders medicines
For coverage information about Novo Nordisk hemophilia and rare bleeding disorders medicines, connect with a NovoCare® representative at 844‑668‑6732
There are limits to the ways in which Novo Nordisk can support patients with government-funded insurance.
For patients with diabetes, please call 844-Novo4Me (844-668-6463) to discuss other options that may be available.
For patients with obesity, growth-related disorders, or hemophilia and bleeding disorders, please contact your prescription insurance provider to discuss options.
We have assistance programs and savings offers which may help reduce the cost of your insulin or provide it at no cost, depending on your situation.
No, there are no longer savings offers available for these products.
If you have questions about your copay offer, please contact the following numbers for your medicine:
Diabetes medicines
Fiasp® (insulin aspart) injection 100 U/mL—833-992-3299
NovoLog® (insulin aspart) injection 100 U/mL—833-992-3299
NovoLog® Mix 70/30 (insulin aspart protamine and insulin aspart) injectable suspension 100 U/mL—833-992-3299
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg—877-304-6855
RYBELSUS® (semaglutide) tablets 7 mg or 14 mg—877-304-6855
Tresiba® (insulin degludec) injection 100 U/mL or 200 U/mL—833-992-3299
Other products
ZEGALOGUE® (dasiglucagon) injection 0.6 mg/0.6 mL—833-992-3299
Obesity medicines
Wegovy® (semaglutide) injection 2.4 mg—888-793-1218
Primary hyperoxaluria type 1 (PH1) medicine
Rivfloza® (nedosiran) injection 80 mg, 128 mg, or 160 mg—844-906-5099
Growth-related disorders medicines
Norditropin® (somatropin) injection 5 mg, 10 mg, 15 mg, 30 mg pens—866‑316‑2404
Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, 15 mg pens—866-316-2404
Hemophilia and rare bleeding disorders medicines
For all hemophilia and rare bleeding disorder medications, please call 844‑668‑6732
Do not share your Ozempic® pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Ozempic® may cause serious side effects, including:
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used:
It is not known if Ozempic® can be used in people who have had pancreatitis.
Ozempic® is not for use in people with type 1 diabetes.
It is not known if Ozempic® is safe and effective for use in children under 18 years of age.
Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, herbal supplements, and other medicines to treat diabetes, including insulin or sulfonylureas.
Ozempic® may cause serious side effects, including:
The most common side effects of Ozempic® may include nausea, vomiting, diarrhea, stomach (abdominal) pain, and constipation.
Please see Prescribing Information and Medication Guide for Ozempic®.
Ozempic® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
RYBELSUS® may cause serious side effects, including:
Do not use RYBELSUS® if:
RYBELSUS® (semaglutide) tablets 7 mg or 14 mg is a prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.
Before using RYBELSUS®, tell your healthcare provider if you have any other medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RYBELSUS® may affect the way some medicines work and some medicines may affect the way RYBELSUS® works.
RYBELSUS® may cause serious side effects, including:
The most common side effects of RYBELSUS® may include nausea, stomach (abdominal) pain, diarrhea, decreased appetite, vomiting, and constipation. Nausea, vomiting, and diarrhea are most common when you first start RYBELSUS®.
Please see Prescribing Information and Medication Guide for RYBELSUS®.
RYBELSUS® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
Victoza® may cause serious side effects, including:
Do not use Victoza® if:
Victoza® (liraglutide) injection 1.2 mg or 1.8 mg is an injectable prescription medicine used:
Victoza® is not for use in people with type 1 diabetes. It should not be used with other medicines that contain liraglutide. It is not known if Victoza® is safe and effective to lower blood sugar in children under 10 years of age.
Before using Victoza®, tell your health care provider if you:
Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, herbal supplements, and other medicines to treat diabetes, including insulin or sulfonylureas.
Victoza® may cause serious side effects, including:
The most common side effects of Victoza® may include nausea, diarrhea, vomiting, decreased appetite, indigestion, and constipation.
Please see Prescribing Information and Medication Guide for Victoza®.
Victoza® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
Xultophy® 100/3.6 may cause serious side effects, including:
Xultophy® 100/3.6 is an injectable prescription medicine that contains 2 diabetes medicines, insulin degludec, 100 units/mL, and liraglutide, 3.6 mg/mL. Xultophy® 100/3.6 should be used along with diet and exercise to lower blood sugar (glucose) in adults with type 2 diabetes mellitus.
Do not use Xultophy® 100/3.6 if:
Tell your health care provider about all your medical conditions, including if you:
Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Before using Xultophy® 100/3.6, talk to your health care provider about low blood sugar and how to manage it.
Your dose of Xultophy® 100/3.6 may need to change because of change in level of physical activity or exercise, weight gain or loss, increased stress, illness, change in diet, or other medicines you take.
Xultophy® 100/3.6 may cause serious side effects that can be life-threatening, including:
The most common side effects of Xultophy® 100/3.6 may include stuffy or runny nose, sore throat, headache, nausea, diarrhea, increased blood levels of lipase, and upper respiratory tract infection.
Please see Prescribing Information and Medication Guide for Xultophy® 100/3.6.
Xultophy® 100/3.6 is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
Do not share your Fiasp® with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Do not take Fiasp® if:
Before taking Fiasp® tell your health care provider about all your medical conditions including, if you:
Talk to your health care provider about low blood sugar and how to manage it.
Change (rotate) your injection sites within the area you choose with each injection to reduce your risk of getting pits in skin or thickened skin (lipodystrophy) and skin with lumps (localized cutaneous amyloidosis) at the injection sites.
Serious side effects can lead to death, including:
Your insulin dose may need to change because of:
Common side effects of Fiasp® may include:
Please see Prescribing Information for Fiasp®.
Fiasp® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
Do not share your Levemir® FlexPen® with other people, even if the needle has been changed. Do not share needles or syringes with another person. You may give other people a serious infection or get a serious infection from them.
Do not take Levemir® if:
Before taking Levemir®, tell your healthcare provider about all your medical conditions including, if you:
Tell your healthcare provider all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Before you start taking Levemir®, talk to your healthcare provider about low blood sugar and how to manage it.
Serious side effects can lead to death, including:
Other common side effects include:
Your insulin dose may need to change because of:
Please see Prescribing Information for Levemir®.
Levemir® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
Do not share your NovoLog® FlexPen®, NovoLog® FlexTouch®, PenFill® cartridge or PenFill® cartridge compatible insulin delivery device with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Do not take NovoLog® if:
Before taking NovoLog®, tell your health care provider about all your medical conditions including, if you are:
Talk to your health care provider about how to manage low blood sugar.
Serious side effects can lead to death, including:
Low blood sugar. Some signs and symptoms include:
Your insulin dose may need to change because of:
Other common side effects may include:
Get emergency medical help if you have:
Please see Prescribing Information for NovoLog®.
NovoLog® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
Do not share your NovoLog® Mix 70/30 FlexPen® with other people, even if the needle has been changed. Do not share needles or syringes with another person. You may give other people a serious infection, or get a serious infection from them.
Before taking NovoLog® Mix 70/30, tell your healthcare provider about all your medical conditions including, if you are:
Before you start taking NovoLog® Mix 70/30, talk to your health care provider about low blood sugar and how to manage it.
Serious side effects can lead to death, including:
Low blood sugar (hypoglycemia). Some signs and symptoms include:
Your insulin dose may need to change because of:
Other common side effects may include:
Get emergency medical help if you have:
Please see Prescribing Information for NovoLog® Mix 70/30.
NovoLog® Mix 70/30 is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
Do not share your Tresiba® FlexTouch® with other people, even if the needle has been changed. Do not share needles or syringes with another person. You may give other people a serious infection, or get a serious infection from them.
Do not take Tresiba® if you:
Before taking Tresiba®, tell your health care provider about all your medical conditions, including if you are:
Talk to your health care provider about low blood sugar and how to manage it.
Tresiba® may cause serious side effects that can be life-threatening, including:
Your insulin dose may need to change because of change in level of physical activity or exercise, increased stress, change in diet, weight gain or loss, or illness.
Get emergency medical help if you have trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion.
Please see Prescribing Information for Tresiba®.
Tresiba® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
ZEGALOGUE® (dasiglucagon) injection is a prescription medicine used to treat very low blood sugar (severe hypoglycemia) in people with diabetes aged 6 years and older. It is not known if ZEGALOGUE® is safe and effective in children under 6 years of age.
Do not use ZEGALOGUE® if you:
Before using ZEGALOGUE®, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
ZEGALOGUE® may cause serious side effects, including:
The most common side effects of ZEGALOGUE® include: in adults: nausea, vomiting, headache, diarrhea, and injection site pain; in children: nausea, vomiting, headache, and injection site pain. These are not all the possible side effects of ZEGALOGUE®.
Please see Prescribing Information for ZEGALOGUE®.
Wegovy® may cause serious side effects, including:
Wegovy® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity:
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® is safe and effective for use in children under 12 years of age.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
Wegovy® may cause serious side effects, including:
The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.
Please see Prescribing Information and Medication Guide for Wegovy®.
Wegovy® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
Do not share your Saxenda® pen with others even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.
Serious side effects may happen in people who take Saxenda®, including:
Saxenda® (liraglutide) injection 3 mg is an injectable prescription medicine used for adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30), and children aged 12-17 years with a body weight above 132 pounds (60 kg) and obesity to help them lose weight and keep the weight off. Saxenda® should be used with a reduced calorie diet and increased physical activity.
Do not use Saxenda® if:
Before taking Saxenda®, tell your health care provider about all of your medical conditions, including if you:
Tell your health care provider about all the medicines you take, including prescription, over-the-counter medicines, vitamins, and herbal supplements. Saxenda® slows stomach emptying and can affect medicines that need to pass through the stomach quickly. Saxenda® may affect the way some medicines work and some other medicines may affect the way Saxenda® works. Tell your health care provider if you take diabetes medicines, especially insulin and sulfonylurea medicines.
Saxenda® may cause serious side effects, including:
The most common side effects of Saxenda® in adults include nausea, diarrhea, constipation, vomiting, injection site reaction, low blood sugar (hypoglycemia), headache, tiredness (fatigue), dizziness, stomach pain, and change in enzyme (lipase) levels in your blood. Additional common side effects in children are fever and gastroenteritis.
Please see Prescribing Information and Medication Guide for Saxenda®.
Saxenda® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
Rivfloza® (nedosiran) injection 80 mg, 128 mg, or 160 mg is a prescription medicine used to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function.
It is not known if Rivfloza® is safe and effective in children younger than 9 years of age.
The most common side effects of Rivfloza® include injection site reactions, such as reddening, pain, bruising, rash, or dimple at the site of injection.
Please see Rivfloza® Prescribing Information.
Rivfloza® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
Norditropin® is a prescription medicine that contains human growth hormone and is used to treat:
Before taking Norditropin®, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Norditropin® may affect how other medicines work, and other medicines may affect how Norditropin® works.
Norditropin® may cause serious side effects, including:
The most common side effects of Norditropin® include:
Please see Prescribing Information for Norditropin®.
Norditropin® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Before taking Sogroya®, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Sogroya® may affect the way some medicines work, and some medicines may affect how Sogroya® works.
Sogroya® may cause serious side effects, including:
The most common side effects of Sogroya® in children include: common cold, headache, fever, pain in extremity, and reaction to injection
The most common side effects of Sogroya® in adults include: back pain, joint pain, indigestion, sleep problems, dizziness, swelling of the tonsils (tonsillitis), vomiting, high blood pressure, increase in the level of an enzyme in your blood called creatine phosphokinase, weight gain, and low red blood cells (anemia)
Please see Prescribing Information for Sogroya®.
Sogroya® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
Loading....